Speeding up drug development in 9/10 top pharma companies

Patholytix empowers faster, more thorough testing of 100s of drug candidates with GLP-compliant digital pathology. Our end-to-end solution enables seamless digital studies, streamlining workflows for precise, reliable insights. By accelerating pathology reporting, we help top pharma partners advance innovative therapies from preclinical studies to market with confidence and efficiency.

Written by
Colin Doolan
Published on
November 27, 2024
Category
Patholytix
Corporate
AI

Accelerating Drug Development for Leading Pharma Firms

Deciphex’s Patholytix platform is transforming drug development for 9 out of the top 10 pharmaceutical companies, enabling them to test hundreds of drug compounds faster and more thoroughly. By providing end-to-end digital studies workflows that are fully GLP-compliant, Patholytix ensures faster regulatory approvals and more accurate assessments, driving critical innovations to market sooner.

Comprehensive Digital Studies Workflows

Patholytix offers a fully integrated, digital-first workflow for pharmaceutical companies and their CRO partners, allowing them to streamline the entire non-clinical testing process. By automating study management and data analysis, the platform removes the bottlenecks of traditional methods, enabling faster decision-making and improving overall drug safety evaluations.

GLP Compliance and Accuracy

Ensuring Good Laboratory Practice (GLP) compliance is key to accelerating drug development, and Patholytix does this by adhering to stringent regulatory standards. In addition, we provide sophisticated computer system validation support, ensuring all processes are robust, compliant, and ready for inspection. This enables pharmaceutical companies to run studies more efficiently, reducing the time and resources spent on regulatory submissions while maintaining high accuracy in safety assessments.

Speeding Up Compound Testing

With Patholytix, hundreds of drug compounds can be tested simultaneously, allowing companies to identify promising candidates faster. By automating routine tasks and integrating AI-powered analysis, the platform boosts throughput without sacrificing data integrity, ensuring that drugs are evaluated quickly and comprehensively.

AI-Driven Decision Support

Patholytix’s use of AI-driven decision support accelerates drug safety assessments by providing real-time insights and automated quality control. This ensures that preclinical safety studies are completed in record time, providing pathologists with only the highest quality slides for assessment. As a result, the efficiency of drug discovery and development pipelines is improved, helping pharmaceutical companies bring life-saving treatments to market faster.

Resources

Patholytix

Foresight: Enhancing Toxicologic Pathology with AI Decision Support - Through Pathologists Insights

Novartis/Deciphex Collaboration

Share this post

I am the text that will be copied.